Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Kawanami D, Takashi Y (2020) GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Sit still, breathe through your nose, and let the medication do its work
Our providers will review your medical history, discuss your weight loss goals, and determine if injectable medications are appropriate for you
Monitor levels every 6 months given high-risk status
In a study of transgenic mice with a Kras G12D mutation which induces PanINs and eventually pancreatic cancer, treatment with exendin-4 increased higher grade PanIN lesions (35, 38)
By the end, youll be able to: Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulation Understand how receptor signaling differences translate into therapeutic outcomes Evaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liver Analyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protection Appreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going
